MetaCap

Amphastar Pharmaceuticals (AMPH) vs COMPASS Pathways Plc American Depository Shares (CMPS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

COMPASS Pathways Plc American Depository Shares (CMPS) has outperformed Amphastar Pharmaceuticals (AMPH) over the past year, gaining 55.7% versus a gain of 8.6%. Over five years, AMPH leads with a +41.9% price change compared with -75.4% for CMPS. Amphastar Pharmaceuticals is the larger company by market cap ($1.20 billion vs $1.14 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMPH+8.61%CMPS+55.71%
+205%+79%-47%
Nov 21, 20251 yearNov 20, 2026
AMPH+37.74%CMPS-74.09%
+221%+57%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMPH versus CMPS key metrics
MetricAMPHCMPS
Share price$28.25$8.05
Market cap$1.20B$1.14B
1-day change+0.50%-6.94%
YTD return+5.49%+16.67%
1-year return+8.61%+55.71%
5-year return+41.89%-75.42%
P/E ratio (TTM)12.96—
Forward P/E8.43—
EPS (TTM)$2.18$-2.34
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$719.89M—
Revenue growth (YoY)-1.65%—
Net income (latest FY)$98.09M$-287.86M
Gross margin49.46%—
Operating margin19.50%—
Net margin13.63%—
52-week high$31.00$15.87
52-week low$16.65$4.88
Distance from 52-week high-8.87%-49.28%
Analyst consensusholdstrong_buy
Avg. price target upside-13.27%+189.57%
Average volume475.35K3.09M
Shares outstanding42.65M141.71M
Employees1,976156
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CMPS has outperformed AMPH by 47.1 percentage points over the past year.

About Amphastar Pharmaceuticals

AMPH stock →

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,976 employees

About COMPASS Pathways Plc American Depository Shares

CMPS stock →

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa.

Health Care · Biotechnology: Pharmaceutical Preparations · 156 employees

AMPH vs CMPS FAQ

Which is bigger, Amphastar Pharmaceuticals or COMPASS Pathways Plc American Depository Shares?

Amphastar Pharmaceuticals (AMPH) is larger, with a market capitalization of $1.20B compared with $1.14B for COMPASS Pathways Plc American Depository Shares (CMPS).

Which stock has performed better over the past year, AMPH or CMPS?

CMPS returned +55.71% over the past 12 months, compared with +8.61% for AMPH (price return, excluding dividends). Past performance does not predict future results.

Are Amphastar Pharmaceuticals and COMPASS Pathways Plc American Depository Shares in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons